Shares of Monopar Therapeutics Inc. (MNPR) have gained 21.2% over the past four weeks to close the last trading session at $77.15, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$109.91 indicates a potential upside of 42.5%.The average comprises 11 short-term price targets ranging from a low of $85.00 to a high of$142.00, with a standard deviation of $17. While the lowest esti ...